Elena Nikulina

Ocugen, Inc. targets 100s of mutations with gene therapies to address 132 billion dollar vision loss burden

Ocugen, Inc. targets 100s of mutations with gene therapies to address 132 billion dollar vision loss burden
Ocugen gene therapy tackles vision loss

Ocugen, Inc. is advancing one-time gene therapies designed to address hundreds of genetic mutations responsible for vision loss, with ambitions to tackle the 132 billion dollar annual global burden associated with the condition.

In a recent interview with PharmaVoice, Ocugen, Inc. CEO Dr. Shankar Musunuri described gene therapy as a transformative innovation likely to be considered one of the greatest discoveries of the 21st century. The company’s research underscores the growing interest among biotech firms in pioneering treatments for genetic disorders, signaling the ongoing evolution of vision care.

Ocugen has accelerated development of modifier gene therapies targeting major blindness diseases, according to a previous report on innovation in the sector. The company has also recognized women leaders driving gene therapy advancement, marking International Women’s Day with an industry spotlight on female innovators. These efforts highlight the firm's continued focus on research and talent in genetic vision loss treatment.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.